News - Brightlands Venture Partners

Matisse Pharmaceuticals receives INN isupartob sodium recognizing first-in-class drug status for M6229

December 11, 2025

Lely invests in Dutch scale-up Grassa

December 09, 2025

Exit: Fortimedix Surgical acquired by Medtronic

December 01, 2025

Curapath and Cristal Therapeutics Sign Co-Exclusive License of CliCr® Bioconjugation Platform

November 27, 2025

Matisse Pharmaceuticals successfully completes study with prolonged infusion of M6229 in healthy volunteers

November 13, 2025

Qorium secures €22m investment to accelerate cultivated leather commercialisation

November 11, 2025

Psylaris secures new investment to expand digital mental health solutions across Europe

October 22, 2025

BVP 2024 Impact Report Now Available!

October 14, 2025

ReSolved Technologies: “Confidence in the product and the partnership!”

October 06, 2025

AVL MOTION: “Aiming to solve the major challenge: labour shortages!”

September 02, 2025

Matisse Pharmaceuticals & EpiDisease receive EU funding for their eHISTOCURE project

June 26, 2025

Hy2Care® secures €4.5 million in funding to prepare for U.S. clinical trial and commercial expansion

May 14, 2025

More information

If you have any questions or want to know more about us
Contact us